ProCE Banner Series

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

Register now for this live 1-hour workshop to gain expert guidance on the optimal incorporation of TROP-2–targeting antibody–drug conjugates into the care of patients with metastatic breast cancer, including review of the latest clinical data, practical advice for the management of treatment-related adverse events, and discussion of patient cases.

To Register: Please click the green “Learn More” button below. On the next page, select “Register for Virtual Event.” Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for oncology physicians, nurses, pharmacists, physician associates/physician assistants, and other healthcare professionals caring for breast cancer patients.

All Events

Past Events

October

23

2023

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

5:30 PM - 6:30 PM Mountain Time (MT)

In-person

Private Event | Host Group MT, Billings, Montana

October

24

2023

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event | Host Group NY, Franklin, New York

October

24

2023

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

7:30 PM - 8:30 PM Pacific Time (PT)

Virtual

Private Event | Host Group ID, Post Falls, Idaho

October

25

2023

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

12:00 PM - 1:00 PM Eastern Time (ET)

In-person

Private Event | Host Group MD, Townson, Maryland

November

17

2023

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

3:00 PM - 4:00 PM Eastern Time (ET)

Virtual

Virtual Event | Host Group in KY, Lexington, Kentucky

December

11

2023

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice [Open Registration]

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group KY, Lexington, Kentucky

January

11

2024

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

6:00 PM - 7:00 PM Central Time (CT)

In-person

Private Event | Host Group MS, Jackson, Mississippi

January

18

2024

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice [Open Registration]

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group DC, Washington, District of Columbia

January

23

2024

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice [Open Registration]

4:00 PM - 5:00 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group OK, Norman, Oklahoma

February

13

2024

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event, Decatur, Texas

Faculty

ProCE Banner Faculty
Aditya Bardia, MD, MPH

Director, Breast Cancer Research
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

ProCE Banner Faculty
Michael A. Danso, MD

Research Director
Virginia Oncology Associates
Sarah Cannon Research Institute
Norfolk, Virginia

ProCE Banner Faculty
Stephanie Graff, MD, FACP

Director of Breast Oncology
Lifespan Cancer Institute
Co-Lead
Breast Cancer Translational Disease Research Group
Legorreta Cancer Center
Brown University
Associate Professor of Medicine
Warren Alpert Medical School
Brown University
Providence, Rhode Island

ProCE Banner Faculty
Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

ProCE Banner Faculty
Kathleen Harnden, MD, MBA

Director
Breast Medical Oncology
Inova Schar Cancer Institute
Assistant Professor of Medicine
University of Virginia
Fairfax, Virginia

ProCE Banner Faculty
Reshma Mahtani, DO

Chief of Breast Medical Oncology
Medical Oncology
Miami Cancer Institute
Miami, Florida

ProCE Banner Faculty
Mabel Mardones, MD

Physician Partner
Rocky Mountain Cancer Centers
Co-Chair 
USON Breast Cancer Pathways Task Force
Executive Committee Member for Breast Cancer Research 
Sarah Cannon Research Institute
Nashville, Tennessee 

ProCE Banner Faculty
Sarah Sammons, MD

Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Topics

  • Welcome and Introduction
  • TROP-2 Biology and Role as a Therapeutic Target in Breast Cancer
  • Applying Current and Emerging TROP-2‒Targeting ADCs in Previously Treated Metastatic TNBC and HR-Positive/HER2-Negative Breast Cancer
  • Practical AE Management for Optimal Therapeutic Outcomes
  • Future Directions
  • Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of the oncology multidisciplinary care team to apply and explain available clinical data on novel and emerging therapies to individualize care for patients with metastatic breast cancer eligible for treatment with TROP2-targeted therapies.

Target Audience
This educational program is intended for oncology physicians, nurses, pharmacists, physician associates/physician assistants, and other healthcare professionals caring for breast cancer patients.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Elucidate the biological significance of TROP-2 in breast cancer, its prevalence, and the reasoning behind utilizing TROP-2-targeted ADCs
  • Evaluate and differentiate the distinct mechanisms of action among approved and emerging TROP-2-targeted ADCs 
  • Formulate personalized treatment strategies incorporating TROP-2-targeting ADCs for patients with previously treated TNBC or endocrine-resistant HR+/HER2- MBC considering current and emerging efficacy and safety data and practical adverse event management strategies 
  • Assess early data and ongoing clinical trials evaluating TROP-2-targeting ADCs in breast cancer and use this information to refer appropriate individuals for study participation

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-220-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Gilead Sciences, Inc.